A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder

Journal of Clinical Psychiatry

Volumn 72, Issue 4, 2011, Pages 441-447

  Khan, Arif ^a,b   Cutler, Andrew J ^c,d   Kajdasz, Daniel K ^e   Gallipoli, Susan ^e   Athanasiou, Maria ^f   Robinson, Donald S ^g   Whalen, Heidi ^e   Reed, Carol R ^e  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d Florida Clinical Research Center LLC   (United States)

^e Clinical Data Inc   (United States)

^f Athanasiou Consulting LLC   (United States)

^g Worldwide Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VILAZODONE;

ABNORMAL DREAMING; ADULT; AGED; ARTICLE; CHANGES IN SEXUAL FUNCTIONING QUESTIONNAIRE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT CHANGE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZOFURANS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955487404     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06596     Document Type: Article

References (31)

1. Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105. (Pubitemid 37432885)
2. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007;29(2):147-155.
3. Gelenberg AJ. The prevalence and impact of depression. J Clin Psychiatry. 2010;71(3):e06.
4. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54(3):216-226. (Pubitemid 37270614)
5. Egede LE. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry. 2007;29(5):409-416. (Pubitemid 47410305)
6. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. (Pubitemid 43050100)
7. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with anti-depressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653-661. (Pubitemid 36246547)
8. Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr. 2007;12(suppl 13):1-27.
9. Ashton AK, Jamerson BD, Weinstein WL, et al. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res. 2005;66(2):96-106. (Pubitemid 40798035)
10. Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1a receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005;510(1-2):49-57. (Pubitemid 40312389)
11. Dawson LA, Watson JM. Vilazodone: a 5-HT1a receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther. 2009;15(2):107-117.
12. Rickels K, Athanasiou M, Reed C. Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression. Personalized Med. 2009;6(2):217-224.
13. Kehne JH, Bartoszyk GD, Greiner HE, et al. In vitro characterization of vilazodone as a dual-acting serotonin reuptake inhibitor and 5-HT1A receptor partial agonist. Poster presented at: 65th Annual Meeting of the Society of Biological Psychiatry; May 20-22, 2010; New Orleans, LA.
14. 1A receptor agonists and serotonin reuptake inhibitors. J Med Chem. 2004;47(19): 4684-4692. (Pubitemid 39195559)
15. Blier P, Ward NM. Is there a role for 5-HT1a agonists in the treatment of depression? Biol Psychiatry. 2003;53(3):193-203. (Pubitemid 36135929)
16. Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs. 2009;18(11): 1753-1764.
17. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(3):326-333.
18. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. (Pubitemid 9136500)
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
21. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
22. Guy W. Clinical Global Impressions (028-CGI). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976:216-222.
23. Zimmerman M, Posternak MA, Chelminski I. Defining remission on the Montgomery-Asberg Depression Rating Scale. J Clin Psychiatry. 2004;65(2):163-168.
24. Hawley CJ, Gale TM, Sivakumaran T; Hertfordshire Neuroscience Research group. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002;72(2):177-184. (Pubitemid 35012022)
25. Posner K, Brent D, Lucas C, et al. Columbia-Suicide Severity Rating Scale (C-SSRS). http://www.cssrs.columbia.edu/docs/C-SSRS-1-14-09-Baseline.pdf. Accessed February 28, 2011.
26. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33(4):731-745. (Pubitemid 28128129)
27. Keller A, McGarvey EL, Clayton AH. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther. 2006;32(1):43-52.
28. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260.
29. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36(4):578-584. (Pubitemid 34270268)
30. Williams VSL, Baldwin DS, Hogue SL, et al. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry. 2006;67(2):204-210. (Pubitemid 43357465)
31. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4): 357-366. (Pubitemid 34456365)